TERT promoter mutations are rare in parathyroid tumors.
نویسندگان
چکیده
The majority of parathyroid tumors are benign, and parathyroid carcinomas represent a diagnostic challenge with limited treatment options. Multiple endocrine neoplasia type 1 gene and cell division cycle 73 (CDC73) are major genes in parathyroid adenomas and carcinomas respectively. However, a large group of parathyroid tumors remain without defined genetic background. Telomeres are chromosome-capping structures designed to protect DNA integrity. During mitosis, the telomere repeats are gradually shortened, which limits the number of possible cell divisions. In order for cancer cells to escape senescence, alterations in telomere maintenance are required. The telomerase reverse transcriptase (TERT) gene encodes the catalytic subunit of the telomerase complex and is largely responsible for maintaining the telomere length. Mutations in the promoter of the TERT gene may cause alterations in transcription factor binding sites, which leads to TERT overexpression and telomerase activation, as was first described for melanoma (Horn et al. 2013). Recently, the common TERT promoter mutations -146COT (also called C250T) and -124COT (C228T) have been implicated in the development of several endocrine tumors. They have been identified in papillary, follicular, and anaplastic carcinomas of the thyroid, adrenocortical carcinomas, and paragangliomas. Interestingly, the mutations were found to be associated with telomerase activation, telomere length, malignant disease, patient age, and adverse prognosis (Liu et al. 2014). In addition to the potential prognostic value, the ongoing development of telomerase inhibitors for clinical use could provide additional treatment options for patients with aggressive endocrine cancer. Previous studies have identified telomerase activity as well as TERT gene expression in parathyroid carcinomas but not in adenomas or normal parathyroid tissue (Falchetti et al. 1999, Kammori et al. 2003). Additionally, the telomerase inhibitor azidothymidine was able to
منابع مشابه
TERT promoter mutations and telomere length in adult malignant gliomas and recurrences
In this report on 303 gliomas we show the highest frequency of TERT promoter mutations in gliobastomas (80%) followed by oligodendrogliomas (70%) and astrocytomas (39%). We observed positive association between TERT promoter and IDH mutations in oligodendroglial tumors (OR = 26.3; 95% CI 2.5-250.2) and inverse association in primary glioblastomas (OR = 0.13; 95% CI 0.03-0.58). Tumors with TERT ...
متن کاملTERT promoter mutations are a rare event in gastrointestinal stromal tumors.
Recently, the impact of telomere dysregulation on malignant progression has been reported in many cancers. A few studies have examined TERT promoter mutations in gastrointestinal stromal tumors (GISTs). Irregular telomerase activation can be maintained by TERT hot spot alterations and alternative lengthening of telomeres (ALT) characterized by inactivation of either the alpha-thalassemia/mental...
متن کاملTERT Core Promotor Mutations in Early-Onset Bladder Cancer
Activating mutations in the core promoter of the TERT gene have been described in many different tumor entities. In vitro models showed a two- to fourfold increase in transcriptional activity of the TERT promoter through creation of a consensus binding motif for Ets/TCF transcription factors caused by these mutations. TERT core promoter mutations are the most common mutations in bladder cancer ...
متن کاملTERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
CONTEXT Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers. OBJECTIVES We aimed to evaluate the frequency of TERT promoter mutations in thyroid lesions and to investigate the prognostic significance of such mutations in a large cohort of patients with differentiated thyroid carc...
متن کاملTERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities
BACKGROUND Recently, recurrent point mutations in the telomerase reverse transcriptase (TERT) promoter region have been found in many human cancers, leading to a new transcription factor binding site, increased induction of TERT and subsequently to telomere maintenance. We determined the prevalence of TERT promoter mutations in soft tissue sarcomas of 341 patients comprising 16 entities and in ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Endocrine-related cancer
دوره 22 3 شماره
صفحات -
تاریخ انتشار 2015